SSGJ-706+XELOX
Phase 2Small molecule
SSGJ-706+XELOX is one of 50 small molecule programs targeting Intestinal Cancer. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
49
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
94 competitors in Intestinal Cancer
#DrugCompanyPhaseTrials
1Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Keytruda
Merck & Co.Phase 2
Camptosar
PfizerPhase 2
Tukysa
PfizerPhase 2
Fudr
PfizerPhase 2
Pemazyre
IncytePhase 2
Beyfortus
BeiGenePhase 2
Fludara
SanofiPhase 2
Trodelvy
GileadPhase 2
Adrucil
EElorac, Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SSGJ-706+XELOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details